Rynacrom (sodium cromoglycate) in intractable perennial rhinitis.
A double-blind trial of Rynacrom (sodium cromoglycate) was conducted on 39 patients with perennial rhinitis. Improvement in nasal blocking was achieved at a statistical significance while sneezing and rhinorrhoea only reached the 0.1 level. During long term follow up, four patients who had previously required polypectomy for recurrent nasal polypi, had their condition resolved and subsequently controlled by Rynacrom therapy of one year's duration. Sixty percent of the original trial population are also being successfully maintained at minimal dosage.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009298:Nasal Polyps / Q000150:complications / Q000188:drug therapy; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000188:drug therapy*
D010919:Placebos; D004205:Cromolyn Sodium